Apellis Announces Preliminary U.S. Revenues Of Approximately $74M For Syfovre (Pegcetacoplan Injection) In Q3 FY23; Approximately 37,000 Commercial Vials And 10,000 Samples Were Distributed To Physician Practices In Q3
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals has announced preliminary U.S. revenues of approximately $74M for Syfovre (Pegcetacoplan Injection) in Q3 FY23. The company distributed approximately 37,000 commercial vials and 10,000 samples to physician practices during the quarter.
October 05, 2023 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis' Q3 FY23 preliminary U.S. revenues for Syfovre are approximately $74M. The company distributed 37,000 commercial vials and 10,000 samples during the quarter.
The announcement of Apellis' preliminary U.S. revenues for Syfovre in Q3 FY23 indicates a positive financial performance. The distribution of a significant number of commercial vials and samples suggests a strong market presence and demand for the product, which could potentially lead to a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100